Revision 1

Store at -20C

#14130

p70 S6 Kinase 2 Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H M R	Endogenous	60	Rabbit	#Q9UBS0	6199

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

p70 S6 Kinase 2 Antibody recognizes endogenous levels of total p70 S6 kinase 2 (S6K2) protein. This antibody does not cross-react with p70 S6 kinase 1 (S6K1) protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro435 of human p70 S6 kinase 2 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

p70 S6 kinase is a mitogen activated Ser/Thr protein kinase that is required for cell growth and G1 cell cycle progression (1,2). p70 S6 kinase phosphorylates the S6 protein of the 40S ribosomal subunit and is involved in translational control of 5' oligopyrimidine tract mRNAs (1). A second isoform, p85 S6 kinase, is derived from the same gene and is identical to p70 S6 kinase except for 23 extra residues at the amino terminus, which encode a nuclear localizing signal (1). Both isoforms lie on a mitogen activated signaling pathway downstream of phosphoinositide-3 kinase (PI-3K) and the target of rapamycin, FRAP/mTOR, a pathway distinct from the Ras/MAP kinase cascade (1). The activity of p70 S6 kinase is controlled by multiple phosphorylation events located within the catalytic, linker and pseudosubstrate domains (1). Phosphorylation of Thr229 in the catalytic domain and Thr389 in the linker domain are most critical for kinase function (1). Phosphorylation of Thr389, however, most closely correlates with p70 kinase activity *in vivo* (3). Prior phosphorylation of Thr389 is required for the action of phosphoinositide 3-dependent protein kinase 1 (PDK1) on Thr229 (4,5). Phosphorylation of this site is stimulated by growth factors such as insulin, EGF and FGF, as well as by serum and some G-protein-coupled receptor ligands, and is blocked by wortmannin, LY294002 (PI-3K inhibitor) and rapamycin (FRAP/mTOR inhibitor) (1,6,7). Ser411, Thr421 and Ser424 lie within a Ser-Pro-rich region located in the pseudosubstrate region (1). Phosphorylation at these sites is thought to activate p70 S6 kinase via relief of pseudosubstrate suppression (1,2). Another LY294002 and rapamycin sensitive phosphorylation site, Ser371, is an *in vitro* substrate for mTOR and correlates well with the activity of a partially rapamycin resistant mutant p70 S6 kinase (8).
p70 S6 kinase 2 (S6K2) exhibits high homology in the kinase domain and adjacent regulatory region with p70 S6 kinase (S6K1). Similar to S6K1, S6K2 displays both mitogen-dependent and rapamycin-sensitive S6 kinase activity (9,10). S6K2 has been shown to have redundant as well as distinct functions from S6K1 (11,12). Research studies show that S6K2 is commonly expressed at higher levels in tumor samples than in corresponding normal tissues, and may promote cancer cell survival via AKT activation (13,14).

Background References

1. Pullen, N. and Thomas, G. (1997) *FEBS Lett* 410, 78-82.
2. Dufner, A. and Thomas, G. (1999) *Exp Cell Res* 253, 100-9.
3. Weng, Q.P. et al. (1998) *J Biol Chem* 273, 16621-9.
4. Pullen, N. et al. (1998) *Science* 279, 707-10.
5. Alessi, D.R. et al. (1998) *Curr Biol* 8, 69-81.
6. Polakiewicz, R.D. et al. (1998) *J Biol Chem* 273, 23534-41.
7. Fingar, D.C. et al. (2002) *Genes Dev* 16, 1472-87.
8. Saitoh, M. et al. (2002) *J Biol Chem* 277, 20104-12.
9. Gout, I. et al. (1998) *J Biol Chem* 273, 30061-4.
10. Lee-Fruman, K.K. et al. (1999) *Oncogene* 18, 5108-14.
11. Pende, M. et al. (2004) *Mol Cell Biol* 24, 3112-24.
12. Pardo, O.E. et al. (2006) *EMBO J* 25, 3078-88.
13. Sridharan, S. and Basu, A. (2011) *Cancer Res* 71, 2590-9.
14. Pardo, O.E. and Seckl, M.J. (2013) *Front Oncol* 3, 191.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human **M:** Mouse **R:** Rat

Trademarks and Patents

Limited Uses